MarketMoodz
AZN — AstraZeneca PLC
Is AZN overbought or oversold? Here is the current MarketMoodz read.
AstraZeneca PLC (AZN) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of July 5, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $195.15. The rating moved from Neutral to Overbought on July 2, 2026 and has changed 26 times in the last 90 days.
- Public ratingOverbought (as of July 5, 2026)
- Last close$195.15
- Rating changesRating changed 26 times in the last 90 days
- Last changeMoved from Neutral to Overbought on July 2, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - General
Latest MarketMoodz coverage
- Abbisko and AstraZeneca Launch NSCLC Combo Trial After China IND2026-07-02
- AstraZeneca Advances Rare-Bone Drug as Enhertu Wins EU Tumor‑Agnostic Label2026-06-29
- AstraZeneca Wins FDA Nod for Truqap, Opens Targeted Prostate Market2026-06-15
- AstraZeneca’s Oral GLP‑1 Pill Moves to Phase 3, Threatening Injectable Dominance2026-06-09
- Ultomiris Slashes Proteinuria in IgA Nephropathy; AstraZeneca Eyes New Indication2026-06-08
See today's live rating, score and targets
Members see the live hourly rating for AZN — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.